Curatis Holding

Curatis Holding AG reports a **51% revenue increase** to **CHF 7.9 million** in the first half of 2026, its strongest half-year yet. The company also reduces its loss to **CHF -0.4 million** and boosts cash reserves to **CHF 3.6 million**. Progress on its corticorelin (C-PTBE-01) program includes securing an **exclusive Japan license with Neupharma** and advancing manufacturing efforts.

Sep 2026AFPNews article

Curatis Holding AG reports a **51% revenue increase** to **CHF 7.9 million** in H1 2026, its strongest half-year on record. The company also reduces its loss to **CHF -0.4 million** and boosts cash reserves to **CHF 3.6 million**. Progress on its corticorelin (C-PTBE-01) drug candidate includes securing an **exclusive Japan licensing deal with Neupharma** and advancing manufacturing efforts.

Sep 2026ad-hoc-news.deNews article

Curatis Holding AG reports **14% year-over-year revenue growth** in its core business, reaching **CHF 5.2 million** in H1 2025. The company also secured a partnership with **Phoenix Labs**, integrating four products that generated **CHF 5 million** in 2024. Development of **C-PTBE-01 (corticorelin)** drives increased expenses, resulting in a **CHF 1.2 million loss** for the period.

Mar 2026ad-hoc-news.deNews article

Kinarus Therapeutics Holding AG and Curatis AG finalize a binding agreement to merge their businesses through a reverse merger, exchanging Curatis shares for new Kinarus shares. Kinarus, a Swiss-listed drug development company in liquidation, and Curatis, a firm specializing in orphan/ultra-orphan and specialty care diseases, aim to integrate their operations under this structure.

Mar 2024MondaqNews article